Physician profile
Michael Packer
NPI 1659454734
$2,816.26
in general payments reported to CMS, 2019-2025
43 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $368 · 2021: $677 · 2022: $468 · 2023: $390 · 2024: $254 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $256.42 | 2020-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $244.53 | 2020-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $217.89 | 2021-2024 | |
| Amgen INC. | $194.21 | 2019-2025 | Repatha, Otezla |
| Novo Nordisk INC | $177.66 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $174.14 | 2019-2025 | Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $123.23 | 2022-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $119.64 | 2019-2021 | |
| Glaxosmithkline, LLC. | $113.10 | 2019-2024 | Bexsero, Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $95.68 | 2023-2025 | Auvelity |
| Biogen, INC. | $65.51 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $63.89 | 2020-2025 | Gardasil 9, Capvaxive, Rotateq |
| Boston Scientific Corporation | $62.29 | 2019-2023 | |
| Mylan Specialty L.P. | $60.16 | 2020-2022 | |
| Insulet Corporation | $57.57 | 2025 | Omnipod |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Packer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.